Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Trinean to Enter into Global Supply Agreement with QIAGEN

Published: Tuesday, January 21, 2014
Last Updated: Tuesday, January 21, 2014
Bookmark and Share
Trinean to manufacture and supply the QIAxpert - a micro-volume spectrometer for DNA and RNA quantitation and quality analysis.

Trinean has announced that it has entered into a manufacturing and supply agreement with QIAGEN for the production of the QIAxpert, a micro-volume spectrometer for DNA and RNA quantitation and quality analysis.

This platform is a UV/VIS spectrophotometer which contains tailor-made solution for QIAGEN customers using QIAGEN’s DNA and RNA sample technologies and devices for quality control applications.

“We are very pleased with this agreement between QIAGEN and Trinean,” comments Philippe Stas, CEO of Trinean. "Adoption of our technology by QIAGEN, the market leader in DNA and RNA sample technologies, is an important new step in the global validation of our innovative take on UV-VIS spectroscopy.”

“Quality control (QC) is becoming increasingly important in nucleic acid based testing as novel detection technologies become more and more sensitive.” Dietrich Hauffe, Senior VP ,Head of Business Area Life Sciences at QIAGEN adds.

“The QIAxpert system provides a unique combination of accurate quantification and the capability to discriminate between molecules of interest. The system allows us to match high-performance sample technologies, in particular isolation, extraction and purification with high-speed spectrophotometry for confirmatory purposes. It will contribute to superior data output across all analytical workflows using DNA or RNA, from PCR to next generation sequencing. QIAxpert can also allow our customers to make better informed decisions with regards to usage of samples in subsequent downstream processes, reducing the risk of repeat experiments. These benefits can result in significant time and cost savings while at the same time increasing the quality of data output with significant advantages in research, applied and clinical markets.”

“This agreement significantly boosts the market reach of our spectrometry technology”, said Yvan Sergeant, VP Commercial Operations of Trinean. “It combines microfluidics with innovative spectral content profiling software for accurate quantitation of biological samples and further illustrates the importance of our ability to have a sound purity check of biological samples prior to any genetic test.”

The QIAxpert is a customized version of the Xpose reader, launched by Trinean early 2013. The platform redefines manual UV/VIS quantification into a convenient, high speed solution. The drop and read approach avoids time-consuming sample loading and cleaning steps thereby minimizing the hands-on time on the reader.

The full-color touch screen gives single touch access to advanced analytical software, including dye-free specific quantification of DNA, RNA or protein in samples containing interfering components, using Trinean’s proprietary algorithms for UV/VIS spectral deconvolution.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Trinean to be Awarded ISO 9001:2008 Certification
Certification awarded for Trinean’s Quality Management System.
Tuesday, February 03, 2015
Trinean to Appoint New Board Member
Company announced that it appointed Mr Chris van Ingen as independent board member.
Friday, May 02, 2014
Trinean Signs a Global Agreement with Bayer CropScience
Bayer will use Trinean’s technology for biomolecule QC using spectral content profiling.
Wednesday, June 12, 2013
Trinean Secures 1 Million Euro Financing
Capricorn Health-tech Fund to join the investor base.
Wednesday, May 29, 2013
Trinean Appoints New CEO and Secures 2.7 Million Euro Financing
Appointment of Philippe Stas as Company’s new CEO.
Monday, April 30, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos